Monopar Therapeutics Files 8-K Report
Ticker: MNPR · Form: 8-K · Filed: Aug 27, 2024 · CIK: 1645469
| Field | Detail |
|---|---|
| Company | Monopar Therapeutics (MNPR) |
| Form Type | 8-K |
| Filed Date | Aug 27, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
Monopar Therapeutics filed an 8-K, likely containing important updates for investors.
AI Summary
On August 27, 2024, Monopar Therapeutics Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No specific material events or financial figures beyond the filing itself were detailed in the provided text.
Why It Matters
This filing indicates that Monopar Therapeutics is providing updates or disclosures to the SEC, which could contain important information for investors regarding the company's financial status or regulatory compliance.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification and does not contain specific material events or financial data that would indicate a change in risk.
Key Players & Entities
- Monopar Therapeutics Inc. (company) — Registrant
- August 27, 2024 (date) — Date of earliest event reported
- 1000 Skokie Blvd. , Suite 350 , Wilmette , IL 60091 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing by Monopar Therapeutics?
The filing is primarily for Regulation FD disclosures and to report financial statements and exhibits.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is August 27, 2024.
What is the principal executive office address for Monopar Therapeutics?
The principal executive office is located at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091.
What is the trading symbol for Monopar Therapeutics' securities?
The provided text does not specify the trading symbol for Monopar Therapeutics' securities.
In which state is Monopar Therapeutics incorporated?
Monopar Therapeutics Inc. is incorporated in Delaware.
Filing Stats: 428 words · 2 min read · ~1 pages · Grade level 10.5 · Accepted 2024-08-27 16:07:29
Key Financial Figures
- $0.001 — ge on which registered Common Stock , $0.001 par value MNPR The Nasdaq Stock Mar
Filing Documents
- mnpr20240827_8k.htm (8-K) — 25KB
- ex_718945.htm (EX-99.1) — 4KB
- monologo.jpg (GRAPHIC) — 4KB
- 0001437749-24-027846.txt ( ) — 171KB
- mnpr-20240827.xsd (EX-101.SCH) — 3KB
- mnpr-20240827_def.xml (EX-101.DEF) — 12KB
- mnpr-20240827_lab.xml (EX-101.LAB) — 16KB
- mnpr-20240827_pre.xml (EX-101.PRE) — 12KB
- mnpr20240827_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On August 27, 2024, Monopar Therapeutics Inc. (Monopar) issued a press release announcing that Monopar regained compliance with Nasdaq's minimum bid price rule. The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release Dated August 27, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Monopar Therapeutics Inc. Date: August 27, 2024 By: /s/ Karthik Radhakrishnan Name: Karthik Radhakrishnan Title: Chief Financial Officer